JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Support: [email protected]

Track Your Order

Tyrosine Kinase

C5826 AG957

Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins
B8016 UNC2025
1 Citation

Target: MER|FLT3

Summary: orally bioavailable dual MER/FLT3 inhibitor

≥23.85 mg/mL
B4882 PF-06463922

Target: ALK|ROS1

Summary: ALK/ROS1 inhibitor,potent and selective

insoluble in H2O; ≥20.3 mg/mL
B5839 SU6656

Target: Src|Lyn|YES|Fyn

Summary: Src tyrosine kinases inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.55 mg/mL
A8691 Flumatinib mesylate

Summary: PDGRFβ inhibitor

Soluble in DMSO
B1401 Cabozantinib malate (XL184)

Summary: MET andVEGF receptor2 inhibitor

≥31.8 mg/mL
A3906 Vandetanib hydrochloride

Summary: VEGFR/EGFR inhibitor

≥51.2 mg/mL
A3967 Lapatinib Ditosylate

Target: EGFR|ErbB-2

Summary: EGFR/HER2 inhibitor,potent and selective

≥24.3 mg/mL
C3677 PD 166326

Summary: receptor tyrosine kinases inhibitor

≤25 mg/mL
B7853 Tandutinib (MLN518) HCl

Summary: FLT3 inhibitor,potent and selective

≥59.9 mg/mL